• Udita Gupta, Thomas Ruli, Danyaal Buttar, Mohamed Shoreibah, and Meagan Gray.
• Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: ugupta@uabmc.edu.
• Am. J. Med. Sci. 2024 Feb 1; 367 (2): 778877-88.

AbstractMetabolic dysfunction associated steatotic liver disease, previously known as non-alcoholic fatty liver disease, is the most common cause of chronic liver disease in the United States with rapidly rising prevalence. There have been significant changes recently in the field with screening now recommended for patients at risk for significant liver fibrosis in primary care and endocrine settings, along with clear guidance for management of metabolic comorbidities and changes in nomenclature. This paper serves as a summary of recent guidance for the primary care physician focusing on identifying appropriate patients for screening, selecting suitable screening modalities, and determining when referral to specialty care is necessary. The hope is that providers will shift away from past practices of utilizing liver tests alone as a screening tool and shift towards fibrosis screening in patients at risk for significant fibrosis. This culture change will allow for earlier identification of patients at risk for end stage liver disease and serious liver related complications, and overall improved patient care.Copyright © 2023 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

17 keywords...

hide…